Leukocyte glucose index discriminates metabolic dysfunction-associated steatotic liver disease from type 2 diabetes: a finding independent of oral antidiabetic therapy
{{output}}
Aim: This study aimed to evaluate the leukocyte glucose index (LGI) as a discriminator between patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and those with type 2 diabetes mellitus (T2DM), and to ... ...
